At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 136 enrolled
Drug / intervention
etanerceptdrug
Likely dose
etanercept 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomised, Open-label Preliminary Study to Assess the Effects of 2 Regimens of Etanercept on Nail and Skin Symptoms in Patients With Nail Psoriasis and Plaque Psoriasis
Wyeth is now a wholly owned subsidiary of Pfizer·interventional·Posted Dec 27, 2007·Updated Feb 25, 2013
In Brief
A Phase 4 clinical trial evaluating etanercept for Nail Psoriasis and Plaque Psoriasis. Completed, enrolled 136 participants.
Detailed Summary
The purpose of this study is to evaluate if Etanercept administered at a higher initial dose provides greater improvement in nail and skin psoriasis symptoms than a regimen with a lower initial dose.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNail Psoriasis, Plaque Psoriasis
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2007
First PostedDec 2007
Primary CompletionAug 2009
Study CompletionOct 2009
TodayJul 2026
First PostedDec 27, 2007
Enrollment StartSep 1, 2007
Primary CompletionAug 1, 2009
Study CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 18.5 years ago
Interventions
etanerceptdrug
Subjects randomized to Arm 1 shall be treated with ETN 50 mg twice weekly for 12 weeks reducing thereafter to ETN 50 mg once weekly to 24 weeks. Subjects randomized to Arm 2 shall be treated with ETN 50 mg once weekly for the entire 24 week treatment period.